Novaliq receives positive CHMP opinion for Vevizye in treatment of dry eye disease
The positive opinion comes with the recommendation that ciclosporin 0.1% be granted marketing authorisation in the European Union
ASRS 2024: Clinical characterisation of HK1 associated with retinitis pigmentosa
At this year's ASRS meeting, Patrick C. Staropoli, MD, discussed his presentation about autosomal dominant pericentral retinitis pigmentosa
ASRS 2024: Sickle cell retinopathy and measurements with dynamic OCT angiography
Richard B. Rosen, MD, recipient of the ASRS Founders Award for 2024, discusses his presentation at the meeting
ASRS 2024: Social determinants of vision health in patients with rhegmatogenous retinal detachments
At this year's ASRS meeting, Sally S. Ong, MD, shared results from a 10-year study on socioeconomic barriers and visual outcomes
ASRS 2024: Examining 36-month outcomes of fluocinolone acetonide 0.18 with the CALM registry study
Ashkan Abbey, MD, discusses 36-month outcomes of real-world patients receiving fluocinolone acetonide 0.18 mg
ASRS 2024: A novel approach to myopic traction maculopathy
Nikoloz Labauri, MD, FVRS, speaks about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy at ASRS 2024
ASRS 2024: Aflibercept 8 mg and 2 mg, DME, and IOP outcomes in the phase 2/3 PHOTON trial
Jordana Fein, MD, MS, speaks about intraocular pressure outcomes in patients receiving aflibercept through week 48 of the PHOTON trial
Higher Molar Dose and Its Translation into Clinical Practice
ASRS 2024: Multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of GA in dry AMD
Eleonora Lad, MD, PhD, discusses multiwavelength photobiomodulation significantly reduces risk for vision loss and onset of GA in dry AMD
ASRS 2024: Intraoperative fluorescein angiography reduces the rate of postoperative vitreous hemorrhage
Alan Franklin, MD, PhD, FASRS, a retina specialist in Mobile, Alabama spoke about his presentation, "Intraoperative Fluorescein Angiography Reduces the Rate of Postoperative Vitreous Hemorrhage."
ASRS 2024: Long-term results of macular hole surgery with long-acting gas tamponade
John Thompson, MD, discusses long-term results of using ICG to peel ILM in the treatment of macular holes
ASRS 2024: 100-week results from the RESTORE trial showcase retinitis pigmentosa outcomes
Michael Singer, MD, speaks at the American Society of Retina Specialists meeting
ASRS 2024: Diabetic retinopathy lesions and assessing disease severity over time
Paolo Antonio Silva, MD, discussed his upcoming ASRS presentation on diabetic retinopathy lesions
ASRS 2024: IOP outcomes following suprachoroidal triamcinolone acetonide use in non-infectious uveitis
Ahead of the ASRS meeting in Stockholm, Sweden, Danny Mammo, MD, discusses use of suprachoroidal triamcinolone acetonide in non-infectious uveitis
ASRS 2024: First-time results from a phase 1b study of FAS inhibition with ONL-1204
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204 for the treatment of geographic atrophy
ASRS 2024: Examining real-world use of faricimab through the FARETINA-DME Study
Theodore Leng, MD, MS, speaks about his ASRS presentation, focusing on the FARETINA-DME Study
ASRS 2024: Geographic atrophy findings from part 1 of the Phase 2/3 SIGLEC trial
Ahead of the ASRS meeting, Rishi P. Singh, MD, previews results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy
ASRS 2024: Continuous treatment of DME with a port delivery system for ranibizumab
Carl C. Awh, MD, FASRS, gives an overview of the Phase 3 Pagoda trial year 2 results
ASRS 2024: 72-Week results from the Phase 3 BALATON and COMINO trials
Carl J. Danzig, MD, discusses efficacy, safety, and durability of faricimab in macular oedema due to retinal vein occlusion
ASRS 2024: Sustainability expert panel demonstrates how retina specialists go green
This year, the ASRS meeting will feature an expert panel on sustainability — learn more from panelist Martin Zinkernagel, MD, PhD
ASRS 2024: Geographic atrophy, lesion growth and outer retinal tubulation
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal geographic atrophy
What are attendees most looking forward to at this year's ASRS meeting?
Four retina specialists share what they're most looking forward to at the 2024 ASRS meeting
ASRS 2024: Improving OCTA performance using AI and differential artery-vein analysis
Jennifer I. Lim, MD, FARVO, FASRS, discusses her ASRS presentation, "Differential Artery-Vein Analysis Improves OCTA Performance for Artificial Intelligence Classification of Diabetic Retinopathy"
Industry preview: Eye care companies announce presentations ahead of ASRS meeting
Companies in the retina space announced presentations ahead of the American Society of Retina Specialists meeting, to be held 17-20 July
Alopecia areata and underlying corneal pathologies
Investigators conducted a case-control study to investigate the corneal topography parameters and biomechanics in patients with alopecia areata
Impact report highlights outcomes of Moorfields Eye Charity programmes
The organisation has secured £72.75 million for its new eye health centre
VEGF-C and VEGF-D signaling pathways: Potential targets for treating wet AMD
A novel formulation may prevent blood vessel growth and vascular leakage in the retina
Semaglutide may be associated with non-arteritic ischemic optic neuropathy (NAION)
GLP-1 receptor agonists, such as Wegovy, Ozempic and Novo Nordisk, are becoming more prolific
Beacon Therapeutics announces new board members, funding to support XLRP and AMD programmes
The company has secured $170 million (approximately €157 million) in Series B funding
Preview: The American Society of Retina Specialists meets in Stockholm, Sweden
Extended daylight hours and plentiful outdoor space make Stockholm a memorable destination for meeting attendees